For prescribing information and adverse event reporting, click here

This section of the website is for UK Healthcare Professionals only. 
If you are not a Healthcare Professional, please click here.

This website has been commissioned by Ipsen UK and is intended for a UK audience.

All materials

Unlock the IQIRVO▼ (elafibranor) effect

Primary Biliary Cholangitis (PBC) Video
02:17

For healthcare professionals caring for people prescribed IQIRVO.

Abbreviations
PPAR, peroxisome proliferator-activated receptor; UDCA, ursodeoxycholic acid.

Footnote
*IQIRVO + UDCA met the primary endpoint of cholestasis response, defined as by ALP <1.67 x ULN, and ALP decrease ≥15% and TB ≤ULN. Reduction in ALP and bilirubin is predictive of long-term outcomes.1–5

References

  1. IQIRVO® (elafibranor) Summary of product characteristics (SmPC). 2024
  2. Lammers WJ et al. Gastroenterology. 2014;147(6):1338–1349.
  3. Corpechot C et al. Clin Res Hepatol Gastroenterol. 2022;46(1):101770.
  4. de Veer RC et al. Aliment Pharmacol Ther. 2022;56(9):1408–1418.
  5. Murillo Perez CF et al. Am J Gastroenterol. 2020;115(7):1066–1074.

IQV-UK-000155 | January 2025

Explore more Primary Biliary Cholangitis (PBC) Resources

Explore more Primary Biliary Cholangitis (PBC) Resources

Browse

To access relevant information about Primary Biliary Cholangitis, please confirm the following:

I am a UK Healthcare Professional

This section is for UK healthcare professionals only. Contains promotional information

I am a UK Healthcare Professional

I am a patient

This section provides information to support patients that have been prescribed IQIRVO®▼ (elafibranor).

I am a patient

I am a member of the general public

This section is for members of the general public.

I am a member of the general public

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Reporting of side effects. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Side effects should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone 01753 627777. By reporting side effects, you can help provide more information on the safety of this medicine.